{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["lenvatinib","pembrolizumab"]],"indication":"locally advanced nonmetastatic clear cell renal cell carcinoma","name":"NCT04393350","nct_id":"NCT04393350","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04393350. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive lenvatinib PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatments repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.","label":"Treatment (lenvatinib, pembrolizumab)","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC","National Cancer Institute (NCI)"],"completion_date":{"date":"2026-12-11","type":"ESTIMATED"},"conditions":["Kidney Cancer","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8"],"enrollment":{"count":18,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Lenvatinib","otherNames":["E7080","ER-203492-00","Multi-Kinase Inhibitor E7080"],"type":"DRUG"},{"name":"Lenvatinib Mesylate","otherNames":["4-[3-Chloro-4-(N''-cyclopropylureido)phenoxy]7-methoxyquinoline-6-carboxamide Mesylate","E7080","Lenvima","Multi-Kinase Inhibitor E7080"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["Keytruda","Lambrolizumab","MK-3475","SCH 900475"],"type":"BIOLOGICAL"},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"],"type":"OTHER"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"}],"last_update":"2026-04-20","lead_sponsor":"Emory University","official_title":"WINSHIP4955-20: Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2024-09-13","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (Complete and Partial Responses)","timeFrame":"Baseline until end of Cycle 1 (4 Cycles (12 weeks)"}],"references":[],"start_date":{"date":"2020-06-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT04393350"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04393350"}